Understanding OAZ1: Potential Drug Target and Biomarker for Apoptosis

Target Name: OAZ1

NCBI ID: G4946

OAZ1

Understanding OAZ1: Potential Drug Target and Biomarker for Apoptosis

OAZ1 (AZ1) is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, and kidneys. It is a member of the AIM (apoptosis-induced memory) family of proteins, which are known to play a role in the process of apoptosis, which is a natural response of cells to environmental stressors and is involved in many cellular processes, including cell death and regeneration.

One of the unique features of OAZ1 is its ability to induce apoptosis in cells under normal circumstances, such as when the cell is exposed to stressors or when it is no longer needed. This ability has made OAZ1 a potential drug target, as researchers are interested in understanding how OAZ1 can be used to treat conditions that involve apoptosis, such as cancer, neurodegenerative diseases, and diseases that cause chronic pain.

In addition to its potential as a drug target, OAZ1 has also been shown to be a potential biomarker for a variety of diseases. For example, studies have shown that OAZ1 levels are elevated in the brains of individuals with Alzheimer's disease, and that OAZ1 levels are also elevated in the brains of individuals with Parkinson's disease. Additionally, OAZ1 has been shown to be elevated in the blood of individuals with heart failure, and that it is associated with poor prognosis in patients with cancer.

The role of OAZ1 in apoptosis is still being fully understood, but it is clear that it plays an important role in the process. OAZ1 is involved in the formation of the apoptosis-induced memory, which is a critical component of the stress response that occurs when cells are exposed to environmental stressors.

In addition to its role in apoptosis, OAZ1 is also involved in a variety of other cellular processes. For example, it is involved in the regulation of cell adhesion, and it is known to play a role in the development and maintenance of cancer. Additionally, OAZ1 is involved in the regulation of cell signaling, and it is known to play a role in the development and progression of a variety of diseases, including neurodegenerative diseases.

The potential use of OAZ1 as a drug target is based on its ability to induce apoptosis in cells under normal circumstances, and its potential as a biomarker for a variety of diseases. Further research is needed to fully understand the role of OAZ1 in apoptosis and its potential as a drug and biomarker.

Protein Name: Ornithine Decarboxylase Antizyme 1

Functions: Ornithine decarboxylase (ODC) antizyme protein that negatively regulates ODC activity and intracellular polyamine biosynthesis and uptake in response to increased intracellular polyamine levels. Binds to ODC monomers, inhibiting the assembly of the functional ODC homodimer, and targets the monomers for ubiquitin-independent proteolytic destruction by the 26S proteasome (PubMed:17900240, PubMed:26305948, PubMed:26443277). Triggers ODC degradation by inducing the exposure of a cryptic proteasome-interacting surface of ODC (PubMed:26305948). Stabilizes AZIN2 by interfering with its ubiquitination (PubMed:17900240). Also inhibits cellular uptake of polyamines by inactivating the polyamine uptake transporter. SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1. Involved in the translocation of AZIN2 from ER-Golgi intermediate compartment (ERGIC) to the cytosol (PubMed:12097147)

The "OAZ1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OAZ1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets